We anticipate a profitable buying opportunity for investors in Merck stock following a 15% decline in July. See why we ...

Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or ...

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of ...

He began his career in the pharmaceutical industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK subsidiary, advancing through different roles in the business around the world.

Congress 2024 will be held in Barcelona, Spain from September 13 to 17, 2024. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd("Kelun-Biotech", 6990.HK)will present the following results of its ...

After Summit Therapeutics (NASDAQ:SMMT) said early this week that its lead asset ivonescimab outperformed Merck's (NYSE:MRK) ...

Sun Pharma has acquired the rights from Merck, Sharp & Dohme (MSD) to develop, manufacture, and commercialise Tedizolid Phosphate in India. ABSSSIs, are more challenging to treat due to the ...